Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma that develops from T-cells, a key part of the immune system. It accounts for a small fraction of all lymphomas but is one of the more common T-cell lymphomas, particularly in children and young adults. ALCL comes in several distinct forms, and outcomes vary widely depending on which type a person has.
The Main Types of ALCL
ALCL isn’t a single disease. It’s classified into several subtypes that behave differently and require different treatment approaches.
ALK-positive systemic ALCL is driven by a genetic error where a growth-signaling gene (called ALK) fuses with another gene, creating an abnormal protein that pushes cells to multiply uncontrollably. This subtype tends to affect younger people and carries the better outlook of the systemic forms, with five-year survival rates between 70% and 86%.
ALK-negative systemic ALCL lacks that same genetic fusion. It typically occurs in older adults and is harder to treat. Five-year survival rates range from 30% to 49%, roughly half the rate of the ALK-positive form.
Primary cutaneous ALCL is confined to the skin and has an excellent prognosis. Even when nearby lymph nodes are involved, the five-year survival rate is around 95%. It’s typically ALK-negative, which in the skin-only form does not signal a worse outcome the way it does in systemic disease.
Breast implant-associated ALCL (BIA-ALCL) develops in the tissue and fluid surrounding a breast implant, usually more than a year after implantation. It’s the rarest form and, when caught early, tends to follow a relatively indolent course.
Symptoms and How It Shows Up
Systemic ALCL most commonly appears as painless, swollen lymph nodes. It can affect nodes in the neck, armpits, or groin, and it frequently involves areas outside the lymph nodes as well, including the skin, bone, soft tissue, and lungs. Many people also experience what clinicians call “B symptoms”: unexplained fevers, drenching night sweats, and unintentional weight loss. These systemic symptoms can precede any visible swelling by weeks.
Primary cutaneous ALCL looks different. It usually presents as one or more firm, reddish-brown nodules or tumors on the skin that may ulcerate. These lesions can be mistaken for infections or other skin conditions, which sometimes delays diagnosis.
BIA-ALCL typically shows up as swelling or a feeling of fullness in one breast, often years after implant surgery. The swelling comes from fluid collecting around the implant. Some people notice breast asymmetry or pain, but the hallmark sign is a late-onset fluid collection that wasn’t there before.
How ALCL Is Diagnosed
A biopsy is essential. Under the microscope, ALCL cells are large and irregularly shaped, which is where the “anaplastic” name comes from. The single most important marker is a protein called CD30, which is strongly and uniformly present on the surface of ALCL cells. This strong, diffuse CD30 positivity is what distinguishes ALCL from other T-cell lymphomas where CD30 may appear only faintly or in patches.
Interestingly, ALCL cells often don’t display CD3, a protein found on nearly all normal T-cells. This can make diagnosis tricky because the cancer looks less like a T-cell lymphoma at first glance. Pathologists use additional markers for T-cell origin and test for the ALK protein to determine whether the disease is ALK-positive or ALK-negative. That distinction directly shapes treatment decisions and expected outcomes.
For BIA-ALCL, diagnosis starts with drawing fluid from around the implant. At least 10 to 50 milliliters of fluid is needed for proper analysis, including CD30 staining and genetic testing to confirm the cells are cancerous T-cells rather than a benign inflammatory reaction.
Treatment for Systemic ALCL
Frontline treatment for systemic ALCL has shifted in recent years. The traditional approach was a combination chemotherapy regimen called CHOP, but response rates were modest. A major clinical trial (ECHELON-2) showed that replacing one component of CHOP with brentuximab vedotin, a drug that delivers chemotherapy directly to CD30-positive cells, improved the overall response rate from 72% to 83%. This combination, known as BV-CHP, is now the preferred first-line treatment where it’s available.
Brentuximab vedotin works like a guided missile: it binds to the CD30 protein that ALCL cells display so prominently, then releases a cell-killing agent directly inside the cancer cell. This targeted approach tends to cause fewer side effects than traditional chemotherapy alone while improving effectiveness.
When the Cancer Comes Back
Relapsed or treatment-resistant ALCL requires a different strategy. For ALK-positive disease, ALK inhibitors have shown dramatic responses even in cases where standard chemotherapy failed. Crizotinib, a first-generation ALK inhibitor, received FDA approval in 2021 for relapsed ALK-positive ALCL. A second-generation inhibitor, alectinib, is approved in Japan. These drugs block the abnormal ALK protein that’s driving the cancer’s growth.
Brentuximab vedotin is also effective in the relapsed setting for both ALK-positive and ALK-negative disease. For patients who achieve a complete response after salvage therapy, stem cell transplantation can offer a chance at long-term cure.
Treating Skin-Only and Implant-Associated Forms
Primary cutaneous ALCL is treated far less aggressively than the systemic forms. A single skin tumor can often be cured with surgical removal or localized radiation therapy alone. When multiple skin lesions are present, low-dose methotrexate taken weekly is highly effective. Full multi-drug chemotherapy is reserved for the uncommon situation where disease spreads beyond the skin.
BIA-ALCL that is limited to the fluid around the implant is treated with implant removal and complete removal of the surrounding scar tissue capsule. When the disease hasn’t invaded through the capsule, this surgical approach alone is often sufficient. If the cancer has spread into surrounding tissue or lymph nodes, systemic chemotherapy is added. Lymph node involvement is assessed through full excisional biopsy rather than needle aspiration, since the cancer can involve nodes in a patchy way that a small sample might miss.
ALCL in Children and Adolescents
ALCL is one of the more common lymphomas in children, and outcomes are generally favorable. Across many different chemotherapy regimens tested internationally, event-free survival rates have consistently landed between 65% and 75%, a pattern so consistent that researchers have described it as “astonishingly similar” regardless of the specific drugs, doses, or treatment duration used.
The largest pediatric trial, ALCL99, confirmed an event-free survival rate of 74%. Children with very early-stage disease that’s completely removed surgically can be cured with just three cycles of chemotherapy. Adding brentuximab vedotin to the standard chemotherapy backbone has pushed two-year event-free survival to 79% and overall survival to 97% in recent studies.
Even children who relapse do well. Different salvage approaches lead to overall survival rates approaching 95%. For children who relapse late, a simple regimen of weekly vinblastine given over two years has proven effective, sparing them the toxicity of intensive retreatment.
What Drives the Difference in Outcomes
ALK status is the single biggest factor separating better outcomes from worse ones in systemic ALCL. The ALK-positive form responds well to initial chemotherapy and, when it relapses, can be targeted directly with ALK-inhibiting drugs. The ALK-negative form lacks that targetable vulnerability, which limits treatment options and contributes to its lower survival rates.
Age also matters. ALK-positive ALCL disproportionately affects children and young adults, while ALK-negative ALCL is more common in people over 40. The cutaneous form carries the best prognosis overall, with 95% five-year survival reflecting its tendency to stay localized to the skin rather than spreading through the body.